Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,182 across all filing types
Latest filing 2021-02-02 Board/Management Inform…
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin Announces Appointment of New Independent Director.
Board/Management Information Classification · 100% confidence The document is a formal announcement addressed to stock exchanges regarding the appointment of Mr. Mark D. McDade as an Independent Director of Lupin Limited. It references compliance with Regulation 30 of the SEBI Listing Regulations, which pertains to disclosures about changes in the board or management. The content focuses on the appointment details, background of the appointee, and company information, without any financial data or report content. The document length is under 5,000 characters and serves as a disclosure notice rather than a full report or detailed management discussion. Therefore, it fits the category of Board/Management Information (MANG).
2021-02-02 English
Appointment
Regulatory Filings Classification · 100% confidence The document text contains no substantive content, only a placeholder for an omitted picture and no textual information. The true document length is only 73 characters, indicating it is extremely short and contains no report or announcement details. Given the lack of content, it cannot be classified as any specific report or announcement type. The fallback category for such empty or non-informative filings is Regulatory Filings (RNS).
2021-01-29 English
Mr. Mark D. McDade (DIN: 09037255) was appointed as an Independent Director of the Company, effective January 28, 2021 for a period of five years. i.e. up to January 27, 2026.
Board/Management Information Classification · 100% confidence The document is a formal letter addressed to stock exchanges disclosing the appointment of Mr. Mark D. McDade as an Independent Director of the company, effective January 28, 2021, for a period of five years. It references Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements, which pertains to disclosures about changes in the board or management. The content is clearly about a board/management change announcement rather than a full report or other filing types. The document length is short and focused solely on this announcement, fitting the category of Board/Management Information (MANG).
2021-01-29 English
Investor Presentation-Q3-FY 2020-21.
Investor Presentation Classification · 100% confidence The document is titled 'Q3 FY2021 Investor Presentation' and is addressed as an investor presentation for the third quarter of fiscal year 2021. It contains detailed financial results, business updates, strategic vision, and market performance data for Q3 FY2021. The document is about 15,000 characters long, which is consistent with a detailed presentation rather than a brief announcement. It includes forward-looking statements, segment performance, and operational highlights typical of investor presentations. There is no indication that this is a full quarterly report (IR) with comprehensive financial statements, nor is it an earnings release (ER) which would be shorter and focused on key highlights only. It is also not an annual report or audit report. The document explicitly states it is an 'Investor Presentation' and is submitted pursuant to SEBI regulations. Therefore, the correct classification is Investor Presentation (IP).
2021-01-28 English
Investor Presentation
Regulatory Filings
2021-01-28 English
Lupin Quarter III FY2021 Results.
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of Lupin Limited's unaudited financial results for the quarter and nine months ended December 31, 2020. It includes comprehensive financial data such as sales, EBITDA, PBT, PAT, income statement highlights, balance sheet highlights, and commentary from the Managing Director. The document references the quarter Q3 FY2021 and provides substantive financial figures and analysis, indicating it is a quarterly financial report. It is not merely an announcement of a report or a certification, but contains actual financial statements and detailed performance metrics. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2021-01-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.